pinal cord injury (SCI) remains a devastating problem, with traumatic SCI affecting 12,400 individuals annually and 250,000 living survivors reported to reside in the United States in July 2005. 13 The prevalence of nontraumatic SCI is estimated to be 3-4 times greater than traumatic SCI. 36 A variety of complications, including genitourinary and respiratory complications, often occur after SCI with rehospitalization rates of up to 55% in the 1st year after SCI and around 37% for every year thereafter for 20 years.
tory molecules, 12 and the rise of extracellular glutamate contributing to excitotoxicity. 43 Current acute management strategies of SCI include surgical decompression, 19 maintenance of arterial pressure with fluids and vasoconstrictors, 52 and methylprednisolone, an antiinflammatory corticosteroid that inhibits transmigration of neutrophils and macrophages into the spinal cord, thereby reducing peroxidation of lipids in the cell membrane. 3 However, there remains a need for greater neuroprotective agents to promote long-term recovery after SCI.
Riluzole, a glutamatergic modulator used primarily in amyotrophic lateral sclerosis (ALS), 26 is currently being evaluated for use in SCI. Riluzole activates guanosine triphosphate-binding signal transduction proteins (G-proteins), resulting in inhibition of neurotransmitter release. 14 Riluzole also indirectly inhibits phospholipase A2 (PLA2), preventing release of arachidonic acid, and directly inhibits protein kinase C (PKC). 42 Recent studies have suggested that riluzole is neuroprotective in neurodegenerative and traumatic injuries through its blockade of sodium channel overactivation and modulation of glutamate uptake, 4 as well as its stimulation of brain-derived neurotrophic factor expression. 29 The use and effects of riluzole specifically in SCI, however, remain relatively new.
In this article, we aim to provide an overview of riluzole's potential effectiveness in SCI and review current pharmacological, animal study, and clinical trial findings with this treatment.
Methods
A systematic review to analyze the use of riluzole in SCI was performed through PubMed with articles dating from 1996 to September 2018 (Fig. 1 ). The search term was "riluzole Spinal Cord Injury." This search yielded 99 results. Articles were included within this review if they presented primary human or animal data or investigated the pharmacology of riluzole in spinal cord injury. By this method, 37 experimental studies met the inclusion and exclusion criteria.
The extracted articles were then divided into 3 categories: 1) animal studies describing therapeutic benefit, 2) clinical studies describing outcomes, and 3) pharmacological studies. Two studies contributed findings to both pharmacology and therapeutic benefit in animals. 39, 58 Animal studies were evaluated for study design (in vivo vs in vitro); animal type; injury model; number of animals included in experimental and control groups; dose; timing and route of administration; and outcomes measured by behavior, histopathology, and electrophysiology. Clinical trials were reviewed for study design, number of patients in experimental and control groups, SCI level, American Spinal Injury Association Impairment Scale (AIS) grade, average age, timing and route of administration, dosage, adverse events, and outcomes measured by sensory and motor functional tests. Pharmacological studies were evaluated for study design, subject type, injury model, number of patients in experimental and control groups, timing and route of administration dosage, adverse effects and outcomes measured by electrophysiology, neurotransmitter uptake, receptor expression, and pharmacokinetics.
Results

Pharmacological Studies
Despite extensively published research on the pharmacology of riluzole, there are few studies reporting its effects on SCI. In this review, 8 studies on the pharmacological effect of riluzole in SCI were included. Pharmacological studies described the mechanisms of action and pharmacokinetics of riluzole in vivo, in vitro, and in human studies. The major findings included decreased riluzole bioavailability in the spinal cord after SCI, 10, 15 with 1 study suggesting the opposite; 58 blockage of sodium currents with riluzole after SCI; 25 and increase in glutamate uptake and expression, 3, 38, 53 with 1 study suggesting no effect of riluzole on glutamate release after SCI. 35 A full description of the pharmacology articles within this study can be found in Table 1 .
Animal Studies
Twenty-six animal studies describing the therapeutic effects of riluzole after SCI were included. There were 24 in vivo studies, 1 in vitro study, and 1 mixed study. A total of 520 animals/in vitro specimens were exposed to riluzole and 515 animals/in vitro specimens underwent other treatments for comparison. The average dose of riluzole used was 6.5 mg/kg in 7 in vivo studies in rats with predominantly intraperitoneal administration, with a few exceptions instead involving intrathecal and intracerebroventricular 24 or intravenous administration 33 and rabbits. [31] [32] [33] 39 For behavioral studies, locomotion was evaluated with the rotarod, grid walk, open field, and pelletreaching tasks; strength was evaluated with the inclined plane test; and sensory function was evaluated with the hind paw withdrawal test. A plethora of behavioral studies demonstrated positive effects of riluzole on motor function including locomotion, 21, 27, 34, 38, 48, 58, 57 strength, 1, 47, 48 and stance and stride length. 47, 49 With regard to sensory function, behavioral studies have suggested that riluzole decreases nociception 24 and spastic reflexes, 30 which is both encouraging for reduction of neuropathic behaviors and concerning for decreased response to noxious stimuli. Histopathological experiments have shown that after SCI, riluzole increased rostrocaudal and epicenter tissue sparing with decreased lesion volume, increased axonal sparing, and increased serotonergic fibers. 38, 48, 55 Other studies have shown an increase in glial cell and neuronal survival, 6, 34, 44, 58 decrease in reactive oxygen species, 49 increase in synaptophysin expression in the ventral horn, 47 decrease in capillary fragmentation, 50 decrease in pyknosis and hypoplasia of ventral motor neurons, 49 decrease in lymphocytes and granulocytes, 7 increase in choline acetylcholine transferase staining in motor neurons, 21 decrease in lactate dehydrogenase, 23 decrease in TUNEL staining apoptotic neurons, 32, 58, 57 decrease in macrophages and microglia, 58 and decrease in lipid peroxidation and water content. 1 Electrophysiological experiments have suggested a decrease in muscle spasm, 5 attenuation of altered reflex mechanisms, 47 and increase in amplitude of somatosensory evoked potentials. 58 Key findings within the animal data demonstrate spinal cord tissue sparing with cell survival after SCI, 1, 6, 33, [31] [32] [33] [34] 38, 39, 41, 44, 46, 48, 55, 57, 58 reduced inflam-matory mediators and sequelae, 7, 49 improved locomotion, 1, 7, 21, 27, 30, [31] [32] [33] [34] 38, 44, 49, 55 and decreased aberrant sensory responses. 5, 24 A full description of animal studies and the results from these investigations can be found in Table 2 .
Human Clinical Studies
Three clinical studies were included in this systematic review. The average age of the patients was 39.1 years (range 18-70 years). In total, the percentage of patients included by AIS grade was 42.6% grade A, 25% grade B, 26.6% grade C, and 6.2% grade D. Most patients in the clinical studies included were severely impaired at baseline. The major findings from clinical studies included decreased pain, 37 increased motor functionality, 22 and decreased spastic reflexes 54 after administration of riluzole for SCI. Specifically, with regard to motor function, Meshkini et al. 37 and Grossman et al. 22 demonstrated statistically significant general motor improvement with riluzole at 6 and 3 months after acute SCI, respectively, while Theiss et al. 54 showed strong correlation of riluzole use with lower-limb volitional strength for patients with chronic, incomplete SCI. Of the 3 clinical studies included, only Meshkini et al. 37 evaluated reduction in pain after riluzole use, and only Theiss et al. 54 evaluated attenuation of spastic reflexes. Clinical studies consistently demonstrated incomplete recovery after SCI despite the use of riluzole as manifested by low motor 10, 37 and sensory 37 scores as well as debilitated voluntary contraction. 54 All patients in clinical studies were administered 50 mg of riluzole enterally. However, while Meshkini et al. 37 and Grossman et al. 22 included a longitudinal dose of 50 mg BID (twice daily) for 8 and 4 weeks, respectively, Theiss et al. 54 only included a one-time dose of 50 mg before testing. Overall, riluzole showed promising results with a decrease in neuropathic pain and severity of SCI, 37 increase in motor function 22 for cervical injury, and decrease in spasticity with preservation of normal voluntary movement. 54 However, these benefits were not without risk for complications, as 14%-70% of patients in the Grossman study had elevated liver enzymes and bilirubin levels, implying potentially hepatotoxic effects of riluzole in humans. 22 A full description of clinical studies included within this analysis can be found in Table 3 .
Discussion
This systematic review describes the potential use of riluzole for efficacy after SCI in humans and animals in improving functional and neurological outcomes after SCI, including positive neuroprotective results. 18 Primary and secondary damage in SCI is mediated primarily by excitotoxicity 16 and thus riluzole, a prominent antiglutamatergic agent, 56 has been a treatment of interest for SCI. Increased expression of glutamate transporters (EAAC1, GLST, and GLT-1) has been implicated in SCI with riluzole treatment increasing uptake activity of glutamate and attenuating any neuropathic pain sequelae from SCI. 53 Moreover, riluzole blocks persistent inward sodium currents and fast sodium spikes, which are particularly important in chronic SCI. 25 There is now a consensus that in neurodegenerative disorders, riluzole works predominantly through increasing glutamate uptake in astrocytes and presynaptic neurons,
FIG. 1.
Ninety-nine clinical studies regarding the use of riluzole in spinal cord injury were initially identified. Twenty-seven articles were removed for inadequate access to the full article. Seventy-two papers were fully reviewed. After applying inclusion and exclusion criteria, 37 articles were selected for review and analysis. Twenty-six studies with 24 in vivo studies, 1 in vitro study, and 1 combined study; 520 animals were in the riluzole treatment arm and 515 animals were in comparative control groups.
» CONTINUED FROM PAGE 13 blocking presynaptic release of glutamate, and blocking persistent sodium currents. 11 Of significance, in contrast to ALS where a high bioavailability (> 90%) is reported, 9 riluzole in SCI in humans exhibited a lower maximum concentration and systemic exposure 0-12 hours after dosing. 10 Even more importantly, in SCI, there is inflammation, which increases the spinal cord expression of PgP, a drug efflux transporter, which decreases the bioavailability of riluzole in the spinal cord compared to plasma, so antiinflammatory medications such as COX or LOX-5 inhibitors decrease PgP expression and increase bioavailability of riluzole in the spinal cord. 15 However, other studies have suggested that the half-life of riluzole increases with SCI and remains substantially higher in the spinal cord than in the plasma. 58 The effects of riluzole seem dose-dependent, with glutamatergic uptake activity of 0.1 and 1.0 mM riluzole in spinal cord synaptosomes that are not replicated at higher doses. 2 Careful dose management is likely required for effective treatment of riluzole in humans. Moreover, in one pharmacological study, there was a 30% treatmentassociated mortality with riluzole, 15 suggesting that despite therapeutic benefits, conservative administration of riluzole in SCI is required for most optimal results.
Within the animal studies, there were significant therapeutic benefits of riluzole manifested by increased tissue sparing, 49 and immune cells, 7, 58 while preserving markers of plasticity and structural integrity such as MAP2, 32, 51 synaptophysin, and subunits of the NMDA receptor and AMPA receptor. 47 This neuroprotective effect of riluzole was often augmented by other pharmacological agents, such as methylprednisolone 38, 39 and dantrolene. 34 Moreover, several studies demonstrated dose-dependent, 5 time-dependent, 41, 46 and route-dependent 24 efficacy of riluzole in SCI, suggesting that dose, timing, and route are important factors to consider in clinical SCI. While studies demonstrate poor efficacy of riluzole in select experiments-behaviorally, 34 histologically, 7, 23, 39, 50, 55 or via electrophysiological measurements 46, 50 -no study exclusively reported negative results. Rather, the efficacy of riluzole can be subtherapeutic or inferior to other neuroprotective agents contingent on a variety of aforementioned factors.
Many studies produced negative results, with riluzole having little effect on outcomes. For example, one study showed that riluzole alone without methylprednisolone does not improve locomotion or tissue sparing. 38 Likewise, another study showed that riluzole does not reduce apoptosis or increase motor function or strength after SCI. 7 A similar study showed that riluzole does not affect survival or the phenotype of cells after a neural stem and progenitor cell graft. 23 Sámano et al. 46 suggested that there is no change in peak amplitude of polysynaptic response to dorsal root stimulation or reflex area in vivo, and no change in ventral motor neuron cell survival in vitro with riluzole. However, a variety of studies found the opposite with regard to ventral motor neuron cell survival. 33, 41, 44 Mu et al. 39 suggested that riluzole does not reduce reactive oxygen species or lipid deoxidation, but the opposite was found by Shimizu et al. 49 and Ates et al., 1 respectively. Given the discrepancy in outcomes between animal studies, riluzole may be neuroprotective in SCI on a selective basis. For example, studies have shown that with higher doses, riluzole had longer-lasting and more effective outcomes. 5, 23 However, also with high doses of riluzole, adverse outcomes such as death and respiratory distress have been reported. 58 Of encouragement, early clinical studies suggested that riluzole is efficacious in decreasing neuropathic pain, 37 increasing motor recovery, 22 and decreasing aberrant reflexes. 54 However, given the relatively sparse number of patients (n = 73) and potential hepatotoxic effects of riluzole 22 in SCI, there remains a need for more robust clinical data on safety and therapeutic benefit from the phase 2 and 3 clinical trials. 18 This is especially true considering the wide range of adverse effects reported with riluzole use in ALS, including hypertension, peripheral edema, pancreatitis, 17 neutropenia, renal disease, interstitial lung disease, and hepatotoxicity. The use of riluzole in SCI is documented far more extensively in animal models than in humans. Given this disparity in total subjects, animal studies have greater power, and the neuroprotective effects of riluzole after SCI in animals are well known. As more patients are enrolled in the ongoing phase 2 clinical trial, the effects of riluzole on motor, sensory, and neurological function will become better understood. 18 Thus, the primary limitation of this review includes extrapolation of animal data to the clinical efficacy of riluzole. Moreover, the most common adverse effects of riluzole are described more extensively in ALS than in SCI. According to the National Spinal Cord Injury Center, life expectancy for patients with SCI remains significantly lower than for those without SCI, and this disparity has not been improving since the 1980s. 40 Given the astronomical inpatient and outpatient costs associated with SCI, 20 improving patient outcomes with neuroprotective agents can decrease cost and improve quality of life.
Conclusions
The neuroprotective effects of riluzole in SCI are promising, but the therapeutic benefit of riluzole in SCI must be appreciated in the appropriate clinical context. Success in animal models does not always translate to success in humans. While preliminary human studies suggest that riluzole may have a role in decreasing neuropathic pain and improving motor recovery for patients with SCI, there remains a need to substantiate these data with consistently reported clinical studies. However, other studies have demonstrated adverse effects, including pancreatitis, lung disease, and neutropenia, without conferring much clinical benefit. As the drug advances through the subsequent clinical trial stages, it will be important to titer the dose and timing to maximize benefits in appropriately selected patients to minimize adverse or ineffective outcomes. Nevertheless, these efforts provide the opportunity to expand the existing, limited pharmacological treatment options to mitigate the devastating effects of SCI and to offer patients the possibility of medical options to improve longterm function and pain control.
